A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease

Trial Profile

A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Gantenerumab (Primary) ; JNJ 54861911 (Primary) ; Solanezumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms DIAN-TU
  • Most Recent Events

    • 04 Oct 2017 Status changed from active, no longer recruiting to recruiting.
    • 10 Aug 2017 In this trial, one more drug (JNJ-54861911) is added as a test drug and thus number of treatment arms has increased from 4 to 6. Planned no. of patients changed from 394 to 438. Also there is change in study title where cognitive endpoint parameter is added and purpose also modified.
    • 03 Aug 2017 Planned number of patients changed from 210 to 394.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top